Last reviewed · How we verify

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) — Portfolio Competitive Intelligence Brief

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) pipeline: 0 marketed, 0 filed, 0 Phase 3, 5 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 5 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Pfizer · 2 shared drug classes
  2. Children's Hospital of Fudan University · 1 shared drug class
  3. H. Lee Moffitt Cancer Center and Research Institute · 1 shared drug class
  4. Exelixis · 1 shared drug class
  5. GlaxoSmithKline · 1 shared drug class
  6. Grupo Espanol de Tumores Neuroendocrinos · 1 shared drug class
  7. Chong Kun Dang Pharmaceutical · 1 shared drug class
  8. Astellas Pharma Global Development, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA):

Cite this brief

Drug Landscape (2026). ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/arqule-inc-a-subsidiary-of-merck-sharp-dohme-llc-a-subsidiary-of-merck-co-inc-ra. Accessed 2026-05-16.

Related